Primary mixed hyperlipidemia
Primary mixed hyperlipidemia[edit | edit source]
It is the most common genetic disorder of lipoprotein metabolism . The frequency is estimated at 1: 100 to 1:50. Heredity is usually marked as autosomal recessive.
- Clinical manifestations
- It often occurs in obese and diabetics . There are no xanthomas or arcus corneae; pathological manifestations of atherosklerosis (coronary heart disease, lower limb ischemia) do not begin until adulthood.
- Biochemical findings
- An abnormal lipid finding is usually not detected until adulthood. The serum is clear or opalescent. VLDL (pre-β-lipoproteins), also LDL (β-lipoproteins) and apoprotein B are elevated, [cholesterol]] is between 10-15 mmol / l, triacylglycerols are between 2.26-5.65 mmol / l. HDL-cholesterol and apoprotein C-II and C-III are usually reduced. Lipoprotein electrophoresis shows familial combined hyperlipoproteinemia such as type IIb, IV or even IIa or V. Sometimes another fraction of pre-α (pre-α1 and pre-α2) is evident, caused by an increase in lipoprotein (a) [Lp (a)]. Chylomicrons are not detected on an empty stomach.
- Pathobiochemistry
- The cause is thought to be an abnormally high synthesis of Apo B in the liver, accompanied by increased VLDL production.
- Prognosis
- A common complication is myocardial infarction before the age of 60; an association with diabetes and obesity is common.
- Healing
- Above all, lifestyle modification: weight reduction, diet with lower fat content (preference for fat with unsaturated fatty acids instead of saturated ones) - reduction of cholesterol intake.
- Drug therapy only in patients for whom lifestyle modification has not been shown to be helpful; fibrates, are most often used , ev.resins, (e.g. Lipanthyl® or Gevilon® in combination with Colestide®); sometimes nicotic acid helps.
Familial dysbetalipoproteinemia (ie type III hyperlipoproteinemia, increase in β-VLDL)[edit | edit source]
Dysbetalipoproteinemia (type III hyperlipidemia) is a rare inherited disorder characterized by a defect in the removal of chylomicron and VLDL residues. The underlying disorder is homozygosity for the mutant form of apo E (apo E 2 ), which binds poorly to liver receptors. As a result, chylomicron residues accumulate as well as cholesterol-rich VLDL (β-VLDL)[1].
- Clinical manifestations
- Various forms of xanthomas dominate :
- tuberous xanthomas (in 80%),
- palmar xanthomas (70%) - are characteristic,
- tendon xanthomas (30%),
- eruptive xanthomas (rare).
- Hyperuricaemia and diabetes are observed in about half of patients.
- Early atherosclerotic changes first affect the lower limbs and coronary arteries (in men before the age of 40, in women before the age of 50).
- Biochemical findings
- Opalescent serum; increased both cholesterol and triacylglycerols: S-cholesterol usually above 7.5 mmol / l, sometimes up to 25 mmol / l, S-triacylglycerols 2-10 mmol / l, rarely 20 mmol / l.
Characteristic appearance of ELFO-lipoproteins: "broad" β-fraction (merging pre-β and β fractions). There is an abnormal fraction between VLDL and LDL (so-called β-VLDL) on the polyacrylamide gel. An increase in the cholesterol / triacylglycerol ratio to> 0.30, a decrease in HDL and LDL cholesterol and, conversely, an increase in VLDL, IDL and chylomicron residues are characteristic.
Links[edit | edit source]
Source[edit | edit source]
- MASOPUST, Jaroslav and Richard PRŮŠA. Pathobiochemistry of metabolic pathways. 1st edition. Prague: Charles University, 1999. 182 pp. ISBN 80-238-4589-6 .
Reference[edit | edit source]
- ↑ BURTIS, Carl A, Edward R ASHWOOD a David E BRUNS. Tietz textbook of clinical chemistry and molecular diagnostics. 4. vydání. St. Louis, Mo : Elsevier Saunders, 2006. 2412 s. s. 930. ISBN 978-0-7216-0189-2.